Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.
作者信息
Gil-Bazo Ignacio
机构信息
Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain.
出版信息
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S35-S38. doi: 10.21037/tlcr.2017.11.01.
Abstract
摘要
相似文献
1
Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.阿维鲁单抗——一种用于治疗晚期非小细胞肺癌的新型程序性死亡配体1抑制剂。
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S35-S38. doi: 10.21037/tlcr.2017.11.01.
2
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.avelumab 联合 axitinib 作为晚期透明细胞肾细胞癌（JAVELIN Renal 100）一线治疗的初步结果：一项开放标签、剂量发现和剂量扩展的 1b 期试验。
Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.
3
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.免疫相关不良事件与非小细胞肺癌的程序性细胞死亡蛋白-1 和程序性死亡配体 1 抑制剂相关：PRISMA 系统评价和荟萃分析。
BMC Cancer. 2019 Jun 10;19(1):558. doi: 10.1186/s12885-019-5701-6.
4
Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.使用抗程序性死亡配体1（PD-L1）抗体阿维鲁单抗进行近红外光免疫治疗。
Oncotarget. 2017 Jan 31;8(5):8807-8817. doi: 10.18632/oncotarget.12410.
5
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.晚期肺癌中不断演变的免疫肿瘤格局：非小细胞肺癌的一线治疗
Ther Adv Med Oncol. 2019 Aug 28;11:1758835919870360. doi: 10.1177/1758835919870360. eCollection 2019.
6
Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.免疫检查点抑制剂在非小细胞肺癌中的应用：鸟瞰全局。
Life Sci. 2019 Sep 15;233:116713. doi: 10.1016/j.lfs.2019.116713. Epub 2019 Aug 3.
7
Avelumab: A Review in Metastatic Merkel Cell Carcinoma.avelumab：转移性 Merkel 细胞癌的治疗药物评价。
Target Oncol. 2018 Jun;13(3):409-416. doi: 10.1007/s11523-018-0571-4.
8
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.阿维鲁单抗用于既往接受过治疗的转移性或复发性非小细胞肺癌患者（JAVELIN实体瘤研究）：一项多中心、开放标签的1b期试验的剂量扩展队列研究
Lancet Oncol. 2017 May;18(5):599-610. doi: 10.1016/S1470-2045(17)30240-1. Epub 2017 Mar 31.
9
Which place for avelumab in the management of urothelial carcinoma?阿维鲁单抗在尿路上皮癌治疗中的地位如何？
Expert Opin Biol Ther. 2019 Sep;19(9):863-870. doi: 10.1080/14712598.2019.1637412. Epub 2019 Jul 9.
10
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.非小细胞肺癌中使用程序性死亡1和程序性死亡配体1抑制剂后肺炎的发生率：试验的系统评价和荟萃分析
Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10.
引用本文的文献
1
Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.免疫检查点抑制剂针对 PD-1/PD-L1 轴在 NSCLC 临床治疗中的治疗和全身不良事件。
Cell Transplant. 2021 Jan-Dec;30:9636897211041587. doi: 10.1177/09636897211041587.
2
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.单克隆抗体在非小细胞肺癌中的治疗综述。
Adv Exp Med Biol. 2021;1286:49-64. doi: 10.1007/978-3-030-55035-6_3.
本文引用的文献
1
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
2
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.抗 PD-L1 抗体阿特珠单抗和度伐鲁单抗通过 PD-1/PD-L1 阻断的分子机制。
Sci Rep. 2017 Jul 17;7(1):5532. doi: 10.1038/s41598-017-06002-8.
3
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.程序性死亡蛋白1及程序性死亡配体1抑制在晚期或转移性非小细胞肺癌治疗中的进展
Front Oncol. 2017 Apr 6;7:67. doi: 10.3389/fonc.2017.00067. eCollection 2017.
4
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy.阿维鲁单抗：推进抗程序性死亡配体1免疫疗法的临床试验创新与合作
Ann Oncol. 2017 Jul 1;28(7):1658-1666. doi: 10.1093/annonc/mdx170.
5
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.阿维鲁单抗用于治疗转移性或局部晚期经治实体瘤（JAVELIN实体瘤研究）：一项1a期、多队列、剂量递增试验
Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31.
6
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.阿维鲁单抗用于既往接受过治疗的转移性或复发性非小细胞肺癌患者（JAVELIN实体瘤研究）：一项多中心、开放标签的1b期试验的剂量扩展队列研究
Lancet Oncol. 2017 May;18(5):599-610. doi: 10.1016/S1470-2045(17)30240-1. Epub 2017 Mar 31.
7
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.多次给予抗 PD-L1 人源 IgG1 单克隆抗体avelumab 后的外周免疫组分析。
J Immunother Cancer. 2017 Feb 21;5:20. doi: 10.1186/s40425-017-0220-y. eCollection 2017.
8
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
9
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.阿维鲁单抗治疗化疗难治性转移性默克尔细胞癌患者：一项多中心、单组、开放标签的2期试验。
Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.
10
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.抗程序性死亡配体1（PD-L1）单克隆抗体阿维鲁单抗用于肿瘤治疗的结构基础
Cell Res. 2017 Jan;27(1):151-153. doi: 10.1038/cr.2016.102. Epub 2016 Aug 30.
Zotero 插件